GE HealthCare Technologies Inc.
GEHCDrugs in Pipeline
18
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
44wMarket Overview
Stock performance and market intelligence
1 upcoming, 1 past
Regadenoson Phase 2 Results Expected
Primary completion for Regadenoson trial (NCT04604782) in Myocardial Ischemia
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
DatSCAN
Lewy Body Dementia
DaTSCAN™ Ioflupane (123I) Injection
Parkinsonian Syndrome
SPECT
Parkinson Disease
Sonazoid™
Liver Lesions
123I-mIBG (meta-iodobenzylguanidine)
Heart Failure, Congestive
Gadodiamide Injection
Aorto-iliac Stenosis
[18F] Flutemetamol
Normal Pressure Hydrocephalus
Flutemetamol (18F) Injection
Mild Cognitive Impairment
[18F]Flutemetamol
Alzheimer's Disease
PET MPI
Coronary Artery Disease (CAD)
GE-145 (AN113111) Injection
Healthy
GE-145
Chronic Renal Insufficiency
Regadenoson
Myocardial Ischemia
Ioforminol 160 mgI/mL
Healthy
Flurpiridaz (18F) Injection
Coronary Artery Disease (CAD)
Fluciclatide Injection
Solid Tumors
Fluciclatide Injection - (AH111585 (F18))
High-grade Glioma
AH110690 (18F) Injection
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
DatSCAN | Phase 3 | Lewy Body Dementia | - |
DaTSCAN™ Ioflupane (123I) Injection | Phase 3 | Parkinsonian Syndrome | - |
SPECT | Phase 3 | Parkinson Disease | - |
Sonazoid™ | Phase 3 | Liver Lesions | - |
123I-mIBG (meta-iodobenzylguanidine) | Phase 3 | Heart Failure, Congestive | - |
Gadodiamide Injection | Phase 3 | Aorto-iliac Stenosis | - |
[18F] Flutemetamol | Phase 3 | Normal Pressure Hydrocephalus | - |
Flutemetamol (18F) Injection | Phase 3 | Mild Cognitive Impairment | - |
[18F]Flutemetamol | Phase 3 | Alzheimer's Disease | - |
PET MPI | Phase 3 | Coronary Artery Disease (CAD) | - |
GE-145 (AN113111) Injection | Phase 2 | Healthy | - |
GE-145 | Phase 2 | Chronic Renal Insufficiency | - |
Regadenoson | Phase 2 | Myocardial Ischemia | - |
Ioforminol 160 mgI/mL | Phase 2 | Healthy | - |
Flurpiridaz (18F) Injection | Phase 2 | Coronary Artery Disease (CAD) | - |
Fluciclatide Injection | Phase 2 | Solid Tumors | - |
Fluciclatide Injection - (AH111585 (F18)) | Phase 2 | High-grade Glioma | - |
AH110690 (18F) Injection | Phase 2 | Alzheimer's Disease | - |
Regulatory & News
Approvals, filings, and latest developments